Summary:

Three main drugs are currently available for treatment of CMV infections:
1. ganciclovir (and its oral version, valganciclovir)
2. Foscarnet
3. Cidofovir

Explanation:
Three main drugs are currently available for treatment of CMV infections:
1. ganciclovir (and its oral version, valganciclovir) -
Valganciclovir is a prodrug of ganciclovir that is converted to the parent
compound by intestinal and hepatic esterases. All of the drugs inhibit viral
replication by inhibiting the activity of CMV DNA polymerase.
Ganciclovir must be phosphorylated three times to be active. The first
phosphorylation occurs by the CMV-derived serine/threonine protein kinase
encoded by UL97, while the last two phosphorylations occur by cellular enzymes.
2. Foscarnet - Foscarnet is a noncompetitive inhibitor of CMV DNA polymerase that
acts by blocking the cleavage of pyrophosphate from the deoxynucleotide
triphosphates, preventing chain elongation.
3. Cidofovir - Cidofovir requires two phosphorylation steps, both performed by
cellular enzymes. Phosphorylated forms of ganciclovir and cidofovir slow and
then stop CMV DNA chain elongation by competing with dGTP.